APRIL 1, 2025
A Targeted Treatment for Carbapenem-Resistant Acinetobacter baumannii
The approval of sulbactam-durlobactam for the treatment of carbapenem-resistant Acinetobacter baumannii infections under the FDA fast-track process sets an important precedent for the development of critical antimicrobials for our most resistant organisms. In this monograph, 2 infectious disease specialists review the clinical trial data and early case reports of this important agent, as well as the updated guidance from the Infectious Diseases Society of America.
Download to read this article in PDF format:
A Targeted Treatment for Carbapenem-Resistant Acinetobacter baumannii
This article is in PDF format and it requires Adobe Reader.
If you do not have Adobe Reader installed on your computer then please download and install from the link below.
Download Adobe Reader